Outlook Therapeutics
OTLK
61 hedge funds and large institutions have $8.59M invested in Outlook Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 19 closing their positions.
90,150% more call options, than puts
Call options by funds: $3.61M | Put options by funds: $4K
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
8% less funds holding
Funds holding: 66 → 61 (-5)
17.16% less ownership
Funds ownership: 35.41% → 18.25% (-17%)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
81% less capital invested
Capital invested by funds: $44.7M → $8.59M (-$36.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.15M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$742K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$720K |
| 4 |
Renaissance Technologies
New York
|
+$536K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.9M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.67M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.89M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$2.4M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.21M |
OTLK Hedge Fund Activity: Q4 2024 in Review
61 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2024, worth a combined $8.59M — down 81% from $44.7M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of OTLK and 14 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 23 added.
The largest buyer was UBS Group, adding an estimated $1.15M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.9M sold.
- 61 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2024, down from 66 in Q3 2024.
- Funds reported $8.59M of Outlook Therapeutics stock for Q4 2024, down 81% quarter-over-quarter.
- 14 funds opened new Outlook Therapeutics positions in Q4 2024 and 19 closed out, a net change of -5 holders.
- The largest Outlook Therapeutics buyer in Q4 2024 was UBS Group, an estimated $1.15M added.
- The largest Outlook Therapeutics seller in Q4 2024 was Great Point Partners, an estimated $6.9M sold.
Based on aggregated 13F filings for Q4 2024.